Journal article · 2026

Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis

Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard A. Lafayette, Vladimír Tesař, Hernán Trimarchi, Kevin Carroll, Ian S.D. Roberts, Vivekanand Jha and 13 more

New England Journal of Medicine · Published 22 October 2026 · DOI 10.1056/nejmoa2609127

View at the publisherCite this paper

In brief

“Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis” is a 2026 journal article by Dana V. Rizk and 24 co-authors, published in New England Journal of Medicine. OpenAlex counts 2 citations as of 17 November 2026, which puts it in the top 5% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
2
Most cited in
2026 (2)
Field-weighted impact
7.81
References
14
Authors
25

Abstract

BackgroundSibeprenlimab, a humanized monoclonal antibody, selectively inhibits the cytokine A proliferation-inducing ligand (APRIL), a key driver of IgA nephropathy. Preliminary trial results with regard to the primary end point of the 24-hour urinary protein-to-creatinine ratio at 9 months after treatment as compared with baseline have been reported, but secondary end points, including outcomes regarding estimated… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rizk, D. V., Barratt, J., Suzuki, Y., Zhang, H., Wong, M. G., Liew, A., Lafayette, R. A., Tesař, V., Trimarchi, H., Carroll, K., Roberts, I. S., Jha, V., Quevedo, A., Han, S. H., Yahya, R., Cheung, C. K., Ramachandran, R., Walsh, M., Chacko, B., . . . Perkovic, V. (2026). Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609127

MLA 9

Rizk, Dana V., et al. “Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2609127.

Chicago

Rizk, Dana V., Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard A. Lafayette, et al. 2026. “Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609127.

Harvard

Rizk, D. V. et al. (2026) ‘Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis’, New England Journal of Medicine. doi:10.1056/nejmoa2609127.

IEEE

D. V. Rizk et al., “Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2609127.

BibTeX

@article{rizk2026sibeprenlimab,
  title     = {{Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis}},
  author    = {Rizk, Dana V. and Barratt, Jonathan and Suzuki, Yusuke and Zhang, Hong and Wong, Muh Geot and Liew, Adrian and Lafayette, Richard A. and Tesař, Vladimír and Trimarchi, Hernán and Carroll, Kevin and Roberts, Ian S.D. and Jha, Vivekanand and Quevedo, Alejandra and Han, Seung Hyeok and Yahya, Rosnawati and Cheung, Chee Kay and Ramachandran, Raja and Walsh, Michael and Chacko, Bobby and Praga, Manuel and Chen, JinBor and Suassuna, José and Xia, Jing and Shah, Lokesh N. and Perkovic, Vlado},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  doi       = {10.1056/nejmoa2609127},
  url       = {https://doi.org/10.1056/nejmoa2609127}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies

  • IgA nephropathy
  • monoclonal antibodies
  • estimated glomerular filtration rate
  • renal function decline
  • renal failure
  • urine protein-to-creatinine ratio
  • renal protection
  • pharmacodynamics

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Rizk, D. V., Barratt, J., Suzuki, Y., Zhang, H., Wong, M. G., Liew, A., Lafayette, R. A., Tesař, V., Trimarchi, H., Carroll, K., Roberts, I. S., Jha, V., Quevedo, A., Han, S. H., Yahya, R., Cheung, C. K., Ramachandran, R., Walsh, M., Chacko, B., . . . Perkovic, V. (2026). Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609127

How many times has this paper been cited?

2 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard A. Lafayette, Vladimír Tesař, Hernán Trimarchi, Kevin Carroll, Ian S.D. Roberts, Vivekanand Jha and 13 more.

What is the DOI of this paper?

10.1056/nejmoa2609127, permanently at https://doi.org/10.1056/nejmoa2609127. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.